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Investigation performed at 10 tertiary-care hospitals in the Republic of Korea
Background: There is currently no optimal method for cartilage restoration in large, full-thickness cartilage defects in older patients.
Purpose: To determine whether implantation of a composite of allogeneic umbilical cord blood–derived mesenchymal stem cells
and 4% hyaluronate (UCB-MSC-HA) will result in reliable cartilage restoration in patients with large, full-thickness cartilage defects
and whether any clinical improvements can be maintained up to 5 years postoperatively.
Study Design: Randomized controlled trial; Level of evidence, 1.
Methods: A randomized controlled phase 3 clinical trial was conducted for 48 weeks, and the participants then underwent
extended 5-year observational follow-up. Enrolled were patients with large, full-thickness cartilage defects (International Cartilage
Repair Society [ICRS] grade 4) in a single compartment of the knee joint, as confirmed by arthroscopy. The defect was treated
either with UCB-MSC-HA implantation through mini-arthrotomy or with microfracture. The primary outcome was proportion of
participants who improved by 1 grade on the ICRS Macroscopic Cartilage Repair Assessment (blinded evaluation) at 48-week
arthroscopy. Secondary outcomes included histologic assessment; changes in pain visual analog scale (VAS) score, Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and International Knee Documentation Committee (IKDC) score
from baseline; and adverse events.
Results: Among 114 randomized participants (mean age, 55.9 years; 67% female; body mass index, 26.2 kg/m2), 89 completed
the phase 3 clinical trial and 73 were enrolled in the 5-year follow-up study. The mean defect size was 4.9 cm2 in the UCB-MSC-HA
group and 4.0 cm2 in the microfracture group (P ¼ .051). At 48 weeks, improvement by 1 ICRS grade was seen in 97.7% of the
UCB-MSC-HA group versus 71.7% of the microfracture group (P ¼ .001); the overall histologic assessment score was also
superior in the UCB-MSC-HA group (P ¼ .036). Improvement in VAS pain, WOMAC, and IKDC scores were not significantly dif-
ferent between the groups at 48 weeks, however the clinical results were significantly better in the UCB-MSC-HA group at 3- to 5-
year follow-up (P < .05). There were no differences between the groups in adverse events.
Conclusion: In older patients with symptomatic, large, full-thickness cartilage defects with or without osteoarthritis, UCB-MSC-HA
implantation resulted in improved cartilage grade at second-look arthroscopy and provided more improvement in pain and function up
to 5 years compared with microfracture.
Registration: NCT01041001, NCT01626677 (ClinicalTrials.gov identifier).
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Articular cartilage defects remain a challenging clinical prob-
lem. Currently available treatment options are generally
more applicable to localized, focal defects in relatively young
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patients rather than the large, full-thickness, often bipo-
lar lesions typically found in the osteoarthritic joints of
older patients.25,29 Microfracture is a popular option for
small cartilage defects, but the results are usually inferior
for large chondral defects.10,20,39 Moreover, microfracture
generally leads to fibrous repair tissue with limited dura-
bility, just up to 1 or 2 years.1,48 Autologous chondrocyte
implantation (ACI) is typically recommended for large
lesions, particularly in younger patients, but ACI proce-
dures are less often indicated in the older population
because of the diminished reparative potential of the
autologous chondrocytes.12 Therefore, neither microfrac-
ture nor ACI is generally recommended in large chondral
defects in older patients. However, many older patients
have an active lifestyle and are reluctant to undergo joint
replacement, so an innovative regenerative treatment
option for this population is needed.
Mesenchymal stem cells (MSCs) have recently been pro-
posed as a potential option for cartilage restoration in
elderly patients. MSCs are known to have unique biolog-
ical characteristics, including immunomodulatory and
anti-inflammatory properties and secretion of proregen-
erative cytokines and chemokines.3,30 MSCs can be
obtained from various tissues of the human body.13,26
Umbilical cord blood–derived MSCs (UCB-MSCs) have
advantages over other MSCs, including noninvasive cell
collection, hypoimmunogenicity, and high expansion
capacity.8,19 Moreover, allogeneic MSC implantation has
the advantages of 1-step surgery and better quality control
of the cells compared with a 2-step procedure such as ACI
or a 1-step procedure using autologous cell concentrate
such as bone marrow aspirate concentrate or autologous
adipose tissue–derived cell therapy, which have heteroge-
neous cell populations.18,49
Several preclinical studies have evaluated human UCB-
MSCs combined with hyaluronic acid (HA) hydrogels for
the restoration of full-thickness cartilage defects.4,11,33,34,38
A phase 1/2, first-in-human clinical trial has suggested the
safety and efficacy of UCB-MSCs when combined with 4%
HA hydrogel (UCB-MSC-HA) for the cartilage repair of
osteoarthritic defects in older patients; durable improve-
ment was found up to 7 years after treatment.36 The cur-
rent study was a randomized controlled phase 3 clinical
trial conducted to determine whether implantation of
UCB-MSC-HA results in reliable cartilage restoration
compared with microfracture (control) in patients with
symptomatic, large, full-thickness cartilage defects. The
study and control populations were observed for 5 years
to determine whether any clinical improvements could be
maintained for that duration.
METHODS
Study Design
This randomized, active controlled, phase 3, multicenter
trial was conducted at 10 tertiary-care hospitals between
February 2, 2009, and January 24, 2011. The trial evalu-
ated surgical implantation of an allogeneic UCB-MSC-HA
composite versus microfracture for treating full-thickness
cartilage defect of the femoral condyle in patients who had
knee pain. An observational, extended follow-up study (36,
48, and 60 months) was performed on participants of
the phase 3 portion who consented to the follow-up portion.
The trials were conducted according to current Good
Clinical Practices and principles of the Declaration of Hel-
sinki (1989). Study protocols were approved by institutional
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review boards at each institution and the Ministry of Food
and Drug Safety (MFDS) of South Korea (equivalent to US
Food and Drug Administration) through the investiga-
tional new drug pathway.
Participants
Eligible participants were patients aged >18 years with a
symptomatic, large, full-thickness femoral condyle or troch-
lear cartilage defect (2-9 cm2), International Cartilage
Repair Society (ICRS)23 grade 4, in a single compartment
of the knee joint as confirmed by arthroscopy, regardless of
whether the defect was focal or osteoarthritic. For patients
with multiple lesions, the defect in the most symptomatic
compartment was considered. Major exclusion criteria
included ligament instability of >5 mm or chronic inflam-
matory articular disease, Kellgren-Lawrence grade 4 oste-
oarthritis, or significant deformity (>10 varus/valgus).
More details of the primary inclusion and exclusion criteria
are provided in Appendix Table A1. Informed consent was
obtained from all participants.
Microfracture is not the gold standard for large chondral
defects, especially in older patients; however, the
participants in this clinical trial had experienced failure
of previous nonoperative treatment, and another year of
placebo control during the trial was not considered ethical
or practical by the investigators and the regulatory body
(MFDS). Thus, after a discussion with the MFDS and a
thorough review of previous reports that showed some
clinical benefit of microfracture in similar disease
states,1,48 microfracture was determined as the active
control. Patients were recommended not to take
nonsteroidal anti-inflammatory drugs, pain relievers, or
injections; however, these agents were allowed if needed
by the patients, after consultation with their physicians.
After enrollment, participants were randomized 1:1
through use of a stratified, random, permuted block design
with block size of 4 to 6. Participants who met the inclusion
and exclusion criteria were assigned to either the UCB-
MSC-HA group or the microfracture group, randomly as
described above. All outcomes were assessed by blinded
evaluators. Surgeons and participants could not be
double-blinded because of the differences in surgical
scars—arthrotomy for UCB-MSC-HA and arthroscopy for
microfracture—however, the macroscopic and histologic
evaluations were performed in a completely blinded man-
ner by independent evaluators.
Cell Preparation and Characterization
Allogeneic UCB-MSCs were produced at a cell manufactur-
ing facility operated by MEDIPOST Co Ltd, in full compli-
ance with the Good Manufacturing Practice requirements
of the MFDS as well as with donor screening, cell isolation
and expansion, and quality control measures. In brief,
donor umbilical cord blood was collected from full-term
infants after informed maternal consent and stored in bags
containing anticoagulant. The cord blood was processed
within 24 hours of collection. Mononuclear cells in the
low-density fraction were separated over Histopaque
(density 1.077 g/cm3; Sigma-Aldrich) and then cultured
according to a previously published method.47 The ex vivo
culture-expansion manufacturing process of the UCB-
MSCs is a scaled adaptation of the technique described by
Yang et al47 and involves initial isolation steps to remove
hematopoietic elements, followed by MSC expansion of the
nucleated cells in culture medium (alpha-Minimal Essen-
tial Medium; Gibco BRL) supplemented with 10% fetal
bovine serum. After multiple passage expansion, the
UCB-MSCs are cryopreserved at –150C or colder in the
presence of 10% dimethyl sulfoxide. For use in the clinical
trial, cryopreserved UCB-MSCs were carefully thawed and
subjected to the final passage with harvested cells vialed at
a concentration of 7.5  106 cells per 1.5 mL and released.
Potency, sterility, mycoplasma, and endotoxin testing dur-
ing the manufacturing process and upon final release were
performed in compliance with requirements by the MFDS.
Interventions
For the study population, the UCB-MSC-HA composite was
prepared at the time of surgery in the operating room
(Appendix Figure A1) and implanted as previously reported
in the phase 1/2 clinical trial.35,36 After a standard arthro-
scopic examination to assess cartilage defects, during
which arthroscopic procedures such as debridement of the
cartilage flaps or meniscectomy were performed, a small
longitudinal arthrotomy incision was made alongside the
patellar tendon to expose the cartilage defect on the femoral
condyle. Multiple drill holes (5  5 mm [diameter  depth];
approximately 2 mm apart) were made in the subchondral
bone for insertion of the UCB-MSC-HA composite. In addi-
tion, multiple small drill holes (1.4  5 mm [diameter 
depth]) were made between the 5-mm drill holes for better
lateral integration between the repair tissues from the
5-mm drill holes, based on experience from a previous clin-
ical trial.36 The UCB-MSC-HA composite was carefully
implanted into the 5-mm drill holes to completely fill in the
holes (Figure 1).36 The wound was then closed, and a splint
was applied. In the active control group, the traditional
microfracture technique was performed, which entailed
making multiple awl holes arthroscopically at the subchon-
dral bone.41
All participants complied with standardized posttreat-
ment rehabilitation. Quadriceps sitting and straight leg–
raising exercises were performed from the day of surgery.
Participants were allowed to start active, passive, and
active-assisted range of motion exercises from postopera-
tive day 1, progressing as tolerated. Nonweightbearing
walking with crutches or a walker was encouraged for the
first 12 weeks for the UCB-MSC-HA group and the first 8
weeks for the microfracture group. After the nonweight-
bearing period had passed, partial weightbearing for 4
weeks followed. We educated participants about the reha-
bilitation protocol and emphasized the importance of com-
pliance for successful outcome after cartilage repair
surgery, as is routine practice for other standard cartilage
repair procedures.
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Outcome Measures
The primary outcome of the phase 3 clinical trial was the
proportion of participants with cartilage restoration equiv-
alent to at least 1 grade improvement on the ICRS Macro-
scopic Cartilage Repair Assessment at 48-week
arthroscopic evaluation (see Appendix Table A2 for scor-
ing).43 Secondary outcomes were the ICRS II Histological
Evaluation System score from tissue biopsies23,24 and
changes in 100-mm visual analog scale (VAS) for pain,
Western Ontario and McMaster Universities Osteoarthri-
tis Index (WOMAC),2 and International Knee Documenta-
tion Committee (IKDC) scores15 from baseline to 48 weeks.
Biopsies of the repair tissue taken from the center of the
lesion site during the 48-week arthroscopic evaluation were
used for the histologic assessment.
Owing to differences in the surgical scars, the ICRS
Macroscopic Cartilage Repair Assessment was conducted
in a blinded fashion as follows: Arthroscopic images were
captured and videos were recorded during both the ini-
tial surgical procedure and the second-look arthroscopy
for efficacy evaluation at 48 weeks. Ten investigators
were divided into 2 groups (group 1: HC Lim, BK Lee,
HJ Jeong, CH Choi, CW Ha; group 2: MK Kim, SI Bin,
CH Choi, JD Yoo, JR Yoon), and each group assessed the
arthroscopic images and videos of the other group with-
out any information regarding the treatment assign-
ment. The 5 investigators in each group initially
assessed preoperative and postoperative images and
videos independently using the ICRS Macroscopic Carti-
lage Repair Assessment. The evaluations were collected
and compared to arrive at a final consensus. If agree-
ment was reached by at least 3 of the 5 reviewers, the
3 matching results were selected as the final ICRS
grade. For cases of agreement by <3 reviewers, the final
grade was determined through an open discussion
among the 5 investigators in each group.
The WOMAC is a well-validated, disease-specific measure
of osteoarthritis of the hip or knee that includes pain, stiff-
ness, and function subscales and addresses activities of daily
living.2 The IKDC subjective knee form15 is designed to
measure symptoms and limitations in function and sports
activity for various knee conditions, including cartilage inju-
ries, and has demonstrated strong psychometric characteris-
tics. The IKDC has shown adequate internal consistency and
no remarkable floor or ceiling effects.5
Figure 1. Surgical implantation procedure for the allogeneic human umbilical cord blood–derived mesenchymal stem cell and 4%
hyaluronate (UCB-MSC-HA) composite. (A) Preoperative weightbearing (WB) posteroanterior radiograph (Rosenberg view) shows
osteophyte formation of the right knee of a 54-year-old female patient. She had previously undergone a total knee arthroplasty for
her left knee. (B) The same radiographic view taken at 5-year follow-up shows maintenance of restored medial joint space without
significant deterioration. (C) Arthroscopic inspection and confirmation of International Cartilage Repair Society (ICRS) grade 4
cartilage defect at the initial examination. (D) Mini-arthrotomy and measurement of the size of the full-thickness cartilage defect in
the medial femoral condyle of the patient’s right knee. (E) Multiple drilling with a drill bit of 5-mm diameter, which is larger than the
diameter of holes made during standard microfracture at the subchondral bone. The large drill holes were mainly made for
containment of the UCB-MSC-HA composite. (F) Implantation of the UCB-MSC-HA composite in the 5-mm drill holes. (G, H)
Restored articular cartilage at 48 weeks after implantation, which was assessed as ICRS grade 3 in this case. (I) Safranin O staining
showing abundant presence of glycosaminoglycan in the restored cartilaginous tissue. (J) Type II collagen immunostaining show-
ing abundant type II collagen in the restored cartilaginous tissue.
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At 48 weeks, cylindrical biopsies (2-mm diameter)
included both restored cartilage tissue and subchondral
bone. The biopsies were fixed (4% paraformaldehyde) and
embedded in paraffin. Then, 4 mm–thick sections
were obtained and stained with hematoxylin and eosin for
general morphologic features, Safranin O for glycosamino-
glycan, and Masson trichrome for general collagen distri-
bution. Immunohistochemical staining for collagen types I
and II was also performed. Biopsies were assessed by 2
blinded, independent professional pathologists according
to the ICRS II Histological Evaluation System.24
Safety was assessed by physical examinations, labora-
tory tests, adverse event (AE) monitoring, and 24-week ex
vivo mixed lymphocyte reaction to allogeneic cells. All of the
AEs were categorized using the World Health Organization
Common Toxicity Criteria for Adverse Events.42
In the observational extended follow-up study of 60
months, longer term safety was assessed by any AEs
incurred, and longer term efficacy was assessed by VAS
pain, WOMAC,2 and IKDC scores15 as well as surgical rein-
tervention rates.
Statistical Analysis
We assumed that approximately 40% of the microfracture-
treated participants would have an improved ICRS grade
based on previous reports,10,28 and we sought to determine
whether the ICRS grade would improve in 70% of UCB-
MSC-HA implanted participants. A total of 84 participants
(42 per group) would provide 80% power to detect a differ-
ence of 40% versus 70% in ICRS grade improvement with a
5%, 2-sided alpha level. With a possible 20% dropout rate,
target enrollment was at least 104 participants (52 per
group).
Between-group differences for the primary efficacy out-
come and subgroup analyses (age and lesion size) were per-
formed using the Fisher exact test. ICRS grade distribution
at 48 weeks was compared between groups using the Wil-
coxon rank-sum test. For secondary endpoint comparisons,
the Wilcoxon rank-sum test or 2-sample t test was used for
continuous variables, and the Fisher exact test was used for
binary variables. The last observation carried forward was
used for missing data at 36, 48, and 60 months. All analyses
were performed using SAS 9.3 (SAS Institute), and all P
values were 2-sided.
RESULTS
In the 48-week clinical trial, 124 participants were screened
and 10 participants were excluded after screening; thus, 114
participants were enrolled and randomized to UCB-MSC-HA
(n ¼ 57) or microfracture (n ¼ 57) (Figure 2A). Of these par-
ticipants, 11 did not receive intervention, leaving 103 parti-
cipants (50 in the UCB-MSC-HA group and 53 in the
Assessed for eligibility (n=124)
Exclusion (n=10)
• Not meeting inclusion criteria (n=5)
• Withdrawal of consent (n=5)
Received allocated 
intervention (n=50)
Allocated to UCB-MSCs-HA 
(n=57)





Completed primary endpoint 
assessment at 48 wk by 
second-look arthroscopy 
(n=43)
Completed primary endpoint 





• Not meeting inclusion criteria (n=2)
• Withdrawal of consent (n=5)
Exclusion (n=7)
• Lost to follow-up (n=1)
• Withdrawal of consent (n=6)
Exclusion (n=4)
• Lost to follow-up (n=1)
• Withdrawal of consent (n=3)
Exclusion (n=7)




Assessed for eligibility (n=77)
Exclusion (n=4)
• Re-intervention (n=3)
• Withdrawal of consent (n=1)
UCB-MSCs-HA (n=36)*
• 36 months (n=33)
Lost to follow-up (n=3)
• 48 months (n=28)
Lost to follow-up (n=4)
Withdrew consent (n=3)
AE (n=1)
• 60 months (n=29)




• 36 months: (n=36)
Lost to follow-up (n=1)
• 48 months (n=30)
Re-intervention (n=1)
Withdrew consent (n=6)
• 60 months (n=28)
Re-intervention (n=2)
Withdrew consent (n=7)
Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flow diagram of study participants. (A) Phase 3 clinical trial of 48
weeks. (B) Observational extended follow-up study of 60 months. *Some of the participants were lost to follow-up at specific
follow-up time points only (eg, a participant who was “lost to follow-up” at the 36- and 48-month timepoints could have been
included at the 60-month timepoint, and vice versa). AE, adverse event; UCB-MSCs-HA, umbilical cord blood–derived mesen-
chymal stem cells and 4% hyaluronate.
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microfracture group). Ultimately, 89 participants (86.4%; 43
in the UCB-MSC-HA group and 46 in the microfracture
group) completed the 48-week primary endpoint assessment
by second-look arthroscopy (Figure 2A), and 87 participants
(84.5%) had biopsy samples taken (tissue acquisition failed in
2 participants).
Demographics, lesion characteristics, and baseline
scores were comparable between the 2 groups (Table 1). The
mean age of participants was 55.3 years in the UCB-MSC-
HA group and 54.4 years in the microfracture group; mean
body mass index was 52.7 (UCB-MSC-HA) and 26.7 (micro-
fracture); the male-to-female ratio was similar in both
groups; and osteoarthritis was the most prevalent diagno-
sis in both groups: 95.4% in the UCB-MSC-HA group and
91.3% in the microfracture group (Table 1). The mean
lesion size was 4.9 cm2 in the UCB-MSC-HA group and
4.0 cm2 in the microfracture group (P ¼ .051). All treated
defects were on the femur, mostly on the medial femoral
condyle (83.1%).
Among the 89 participants who completed the initial 48-
week clinical trial, 73 were enrolled in the extended obser-
vational 60-month follow-up study (Figure 2B). Detailed
information on participants of the extended follow-up study
is provided in Appendix Table A3. There were no significant
TABLE 1








Age, y 55.3 ± 8.9 54.4 ± 10.8 .682
Sex >.999
Male 15 (34.9) 16 (34.8)
Female 28 (65.1) 30 (65.2)











1 (2.3) 0 (0.0)
Focal chondral defect 1 (2.3) 4 (8.7)
VAS pain scorec 44.0 ± 12.5 44.6 ± 12.9 .833
WOMAC scored 37.4 ± 15.1 40.4 ± 14.8 .360
IKDC score 42.7 ± 13.9 41.8 ± 13.4 .748
ICRS grade
Grade 1, 2, or 3 0 (0.0) 0 (0.0)
Grade 4 43 (100.0) 46 (100.0)
Lesion size, cm2 4.9 ± 2.0 4.0 ± 1.8 .051
Location
Medial femoral condyle 34 (79.1) 40 (87.0)
Lateral femoral condyle 5 (11.6) 4 (8.7)
Trochlea 4 (9.3) 2 (4.3)




26 (60.5) 26 (56.5) .830
Multicompartmental
osteoarthritis
17 (39.5) 20 (43.5)
Concomitant proceduresc 28 (65.1) 33 (71.7) .648
Meniscectomy 26 (60.5) 27 (58.7) >.999
Treated compartment 25 (58.1) 24 (52.2) .671
Untreated
compartment
2 (4.7) 7 (15.2) .159
Other procedured 10 (23.3) 15 (32.6) .355
aData are reported as n (%) or mean ± SD. ICRS, International
Cartilage Repair Society; IKDC, International Knee Documenta-
tion Committee; K-L, Kellgren-Lawrence; UCB-MSC-HA, umbili-
cal cord blood–derived mesenchymal stem cells and 4%
hyaluronate; VAS, visual analog scale; WOMAC, Western Ontario
and McMaster Universities Osteoarthritis Index.
bTwo-sample t test for continuous variables and chi-square test
for binary variables.
cStudy participant may have received >1 concomitant proce-
dure.
dIncludes plica excision, notchplasty, meniscal repair, cartilag-
inous loose body removal, osteophyte excision, ganglion cyst exci-
sion, synovectomy, and anterior cruciate ligament reconstruction
or debridement.
TABLE 2








Assessment of Cartilage Restoration
Improved (at least 1 ICRS
grade)




Odds ratio (95% CI) 16.55 (2.06-133.03)
Not improved 1 (2.3) 13 (28.3)
ICRS Grade Distribution
ICRS grade .008c
Grade 1 3 (7.0) 1 (2.2)
Grade 2 25 (58.1) 20 (43.5)
Grade 3 14 (32.6) 12 (26.1)
Grade 4 1 (2.3) 13 (28.2)
Subgroup Analysis: Participants With Improvement
of at Least 1 ICRS Grade
Age
<50 y 9/9 (100.0) 11/11 (100.0) NA
50 to 59 y 21/22 (95.5) 13/21 (61.9) .009
60 y 12/12 (100.0) 9/14 (64.3) .043
Initial cartilage defect size
2.0 to 3.0 cm2 8/8 (100.0) 15/15 (100.0) NA
>3.0 to <6.0 cm2 20/20 (100.0) 14/22 (63.6) .004
6.0 cm2 14/15 (93.3) 4/9 (44.4) .015
aData are reported as n (%) unless otherwise indicated. 9/9
means that 9 patients showed minimum grade 1 improvement in
ICRS grade among 9 patients less than 50 years old. ICRS, Inter-
national Cartilage Repair Society Macroscopic Cartilage Repair
Assessment; NA, not applicable; UCB-MSC-HA, umbilical cord
blood–derived mesenchymal stem cells and 4% hyaluronate.
bPearson chi-square test.
cWilcoxon rank-sum test.
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differences in baseline characteristics between the groups
at 60-month follow-up.
Efficacy Outcomes
Phase 3 Clinical Trial at 48 Weeks
The primary outcome analysis revealed that the proportion
of participants showing improvement of 1 ICRS grade at
48 weeks was 97.7% (42/43) in the UCB-MSC-HA group and
71.7% (33/46) in the microfracture group (odds ratio, 16.55;
95% CI, 2.06-133.03; P ¼ .001) (Table 2). The proportion of
participants showing the restored cartilage status as ICRS
Macroscopic Cartilage Repair Assessment grade 1 or 2 was
65.1% in the UCB-MSC-HA group and 45.7% in the micro-
fracture group (Table 2). The distribution of ICRS repair
assessment grade for UCB-MSC-HA versus microfracture
was significantly different (P ¼ .008). Subgroup analyses
according to age (<50, 50-59, and 60 years) demonstrated
that the improvement in ICRS grade was affected by age in
the microfracture group (100%, 61.9%, and 64.3%, respec-
tively) but not in the UCB-MSC-HA group (100%, 95.5%,
and 100%, respectively) (Table 2). Subgroup analyses
according to size of cartilage defect (2.0 to 3.0, >3.0 to
<6.0, and 6.0 cm2) also demonstrated that the efficacy of
microfracture decreased as the lesion size increased (100%,
63.6%, and 44.4%, respectively), but that tendency was not
noticeable in the UCB-MSC-HA group (100%, 100%, and
93.3%, respectively) (Table 2).
Scores on the ICRS Macroscopic Cartilage Repair Assess-
ment were significantly higher in the UCB-MSC-HA group,
both overall and for every subcategory (degree of defect
repair, integration to border zone, and macroscopic appear-
ance) (Table 3). Histologic assessment according to the
ICRS II Histological Evaluation System also revealed that
the UCB-MSC-HA group had better histologic restoration
in terms of the overall score, the subchondral bone assess-
ment, and the mid-/deep zone assessment (Table 3). Both
groups had significantly improved VAS pain, WOMAC, and
IKDC scores at 48 weeks versus baseline (P < .05). No
significant difference was seen between the 2 groups
regarding these clinical parameters at 48 weeks (Figure 3).
Observational Extended Follow-up Study of 60 Months
From 36 to 60 months after intervention, the significant
improvements from baseline regarding VAS pain,
WOMAC, and IKDC scores were maintained in the UCB-
MSC-HA group, whereas the improvements in VAS pain
and WOMAC deteriorated in the microfracture group (Fig-
ure 3). The VAS pain score was significantly better in the
UCB-MSC-HA group compared with the microfracture
group at the 60-month follow-up (Figure 3A). The WOMAC
and IKDC scores were significantly better in the UCB-
MSC-HA group than in the microfracture group at the 36-
and 60-month follow-up (Figure 3, B and C). In addition,
improvement in VAS pain, WOMAC, and IKDC scores at
36- and 60-month follow-up in the UCB-MSC-HA group
was greater than the minimal clinically important
difference (MCID; VAS 13.7,14 IKDC 11.5,16 and WOMAC
11.59), but this was not the case in the microfracture group
(Appendix Table A4).
By the 60-month follow-up, 2 total knee replacements
and 1 osteotomy had been performed in the UCB-MSC-
HA group, whereas 3 total knee replacements, 1 osteotomy,
and 1 meniscectomy had been performed in the microfrac-
ture group (P ¼ .481) (Table 4).
Safety
No significant differences were observed between the UCB-
MSC-HA group and the microfracture group with regard to
overall or specific treatment-emergent AEs in the initial 48-
week clinical trial (Appendix Table A5) or the 60-month
follow-up study (Appendix Table A6). No participant was
withdrawn from the study because of AEs.
Three serious AEs (SAEs) occurred in 3 participants in
the UCB-MSC-HA group, whereas 2 SAEs occurred in 1
participant in the microfracture group within the initial
48 weeks (Table 4). Surgical site pain in the UCB-MSC-
HA group was the only SAE considered by the investigator
as “probably related” to treatment (due to arthrotomy). In
the 60-month follow-up, 8 SAEs occurred in 7 participants
in the UCB-MSC-HA group and 7 SAEs in 5 participants in
the microfracture group (Table 4). None of the SAEs were
considered treatment related by the investigators. The
TABLE 3
Summary of Macroscopic and Histologic Evaluation







ICRS Macroscopic Cartilage Repair Assessment score
Overall 8.4 ± 2.3 6.4 ± 3.5 .017
Degree of defect repair 3.1 ± 0.7 2.5 ± 1.3 .045
Integration to border zone 2.6 ± 0.9 1.9 ± 1.2 .005
Macroscopic appearance 2.7 ± 0.9 2.1 ± 1.2 .015
ICRS II Histological Evaluation System score
Overall 60.2 ± 16.8 51.1 ± 23.0 .036
Tissue morphology 53.2 ± 20.5 51.2 ± 22.4 .689
Matrix staining 54.9 ± 21.3 55.5 ± 20.2 .902
Cell morphology 49.3 ± 22.7 51.4 ± 21.8 .664
Chondrocyte clustering 76.0 ± 14.2 70.9 ± 19.1 .092
Surface architecture 66.0 ± 23.7 67.6 ± 27.2 .917
Basal integration 76.0 ± 14.2 72.6 ± 18.7 .220
Tidemark formation 18.4 ± 23.4 25.9 ± 27.3 .169
Subchondral bone
abnormalities
77.4 ± 14.2 70.0 ± 19.4 .043
Inflammation 96.1 ± 7.3 96.0 ± 5.9 .975
Abnormal calcification 88.4 ± 13.3 84.4 ± 17.2 .237
Vascularization 87.2 ± 25.4 94.0 ± 7.8 .109
Surface assessment 69.5 ± 22.1 58.7 ± 33.4 .077
Mid/deep zone
assessment
76.7 ± 12.3 66.3 ± 24.0 .012
aData are reported as mean ± SD. ICRS, International Cartilage
Repair Society; UCB-MSC-HA, umbilical cord blood–derived mes-
enchymal stem cells and 4% hyaluronate.
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patients who underwent total knee arthroplasty and high
tibial osteotomy were considered to have required the pro-
cedure as a natural course of osteoarthritis and not because
of implantation of the UCB-MSC-HA composite or micro-
fracture. One death due to myocardial infarction (at 41
months postintervention) was reported in the UCB-MSC-
HA group. No immunological reactions were observed in
any of the 43 participants treated with UCB-MSC-HA,
according to the mixed lymphocyte reaction test.
DISCUSSION
The results of the present study demonstrated that implan-
tation of UCB-MSC-HA provides superior cartilage resto-
ration compared with microfracture at 48 weeks after
intervention, meeting the a priori primary endpoint in
patients with symptomatic, large, full-thickness cartilage
defects. The UCB-MSC-HA group demonstrated consistent
improvement in ICRS grade of cartilage repair, even in the
patients and those with larger lesions, whereas microfrac-
ture resulted in unreliable improvement in these groups. Of
note, baseline IKDC score and cartilage restoration with
microfracture in this study were inferior to those of at least
1 other study,40 likely due to older patient age (mean age,
56 vs 34 years) and inclusion of large, full-thickness lesions
in osteoarthritic knees in the present study versus focal
chondral defects treated in the other study. A reliable
regenerative treatment option is not currently available for
large cartilage defects in older patients with osteoarthritis,
and our study results indicate that this novel application of
UCB-MSC-HA may be applicable to these patients. UCB-
MSC-HA may be an alternative treatment option to
unicompartmental knee arthroplasty for those who desire
joint preservation and the maintenance of an active
lifestyle.
Despite the superior structural restoration after implan-
tation of UCB-MSC-HA as assessed macroscopically and
histologically, clinical outcomes such as pain and function
at 48 weeks were not significantly superior to those expe-
rienced by patients who underwent microfracture. That
both groups showed significant improvement in clinical
outcomes at 48 weeks compared with baseline seemed to
Figure 3. Clinical outcomes from baseline to 60-month follow-up in the umbilical cord blood–derived mesenchymal stem cells and
4% hyaluronate (UCB-MSC-HA) versus microfracture groups. Vertical bars indicate 95% CIs for the mean scores. (A) Visual analog
scale (VAS) for pain; (B) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); and (C) International Knee
Documentation Committee (IKDC) score. §2-sample t test. *Wilcoxon rank-sum test on score changes from baseline to the time
point. **2-sample t test on score changes from baseline to the time point. #Sample sizes for follow-up study (36, 48, and 60 months)
include missing data replacements using last observation carried forward (LOCF). The numbers in parentheses indicate the
participants assessed at each time point.
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justify our decision to use microfracture as an active control
rather than placebo.
No reliable gold standard is available to be used as the
active control in studies of large, full-thickness cartilage
defects; however, the results of the current study support
previous findings that microfracture can provide clinical
benefit for this condition for at least 1 year. In this study,
the microfracture group showed deterioration in clinical
outcomes after 3 years, which is compatible with many pre-
vious reports.21,27,28 In the UCB-MSC-HA group, the
improvements in pain and knee function were maintained
without significant deterioration until 5 years after implan-
tation. However, improvements in IKDC score were rela-
tively low, and VAS pain scores of 20 to 30 were found at
final follow-up. Although it is difficult to pinpoint the rea-
son for the relatively low clinical outcomes, the status of
knee osteoarthritis in the older patients in this study popu-
lation could have affected the results.
In this study, clinical outcome improvements were
greater than the MCID only in the UCB-MSC-HA group.
Moreover, most of the clinical outcomes that were signifi-
cantly superior in the UCB-MSC-HA group occurred in the
3 to 5 years after the intervention. We believe the difference
may stem from the better quality of the restored cartilage
tissue in the UCB-MSC-HA group compared with the
microfracture group, as demonstrated by histologic testing
at 48 weeks.
To date, few cartilage repair methods have been clini-
cally successful in large, full-thickness cartilage defects,
which are typical in patients with osteoarthritic knees.6
In this regard, a novel regenerative strategy is needed for
the treatment of such defects, especially in elderly patients.
The UCB-MSC-HA in this study has the advantage of being
available off-the-shelf and requiring only a single-stage
procedure. The previous phase 1/2, single-arm study of
UCB-MSC-HA implantation demonstrated that the
improved clinical outcomes had not significantly deterio-
rated >7 years after treatment.36 The results of the present
study confirmed that cartilage restoration by UCB-MSC-
HA leads to sustained clinical improvement until 5 years
postintervention, which is encouraging for joint preserva-
tion. As osteoarthritic cartilage defects were present in
about 90% of the study participants (see Table 1), we
believe that UCB-MSC-HA is a viable treatment option for
the regenerative treatment of large, full-thickness cartilage
defects, even in osteoarthritic conditions.
Cartilage restoration using culture-expanded autologous
MSCs has previously been attempted; however, the studies
are limited to case reports or case series with small num-
bers of patients.17,22,31,32,37,45 Two randomized clinical
trials (RCTs) examined the efficacy of culture-expanded,
autologous bone marrow–derived MSCs embedded in a col-
lagen gel45 or injected intra-articularly with hyaluronate46
for the treatment of osteoarthritis. However, we believe
that the clinical outcomes in those studies were
confounded by concomitant high tibial osteotomy. In a
double-blind RCT (N ¼ 55) of intra-articular allogeneic,
culture-expanded bone marrow MSCs versus hyaluronate
after partial medial meniscectomy in patients with osteoar-
thritic changes, the authors reported no evidence of struc-
tural cartilage restoration at 1 year, which was the primary
endpoint of the trial.44 Our phase 3, 48-week study seems to
be the first RCT of allogeneic, culture-expanded UCB-MSC
implantation, and the results indicate cartilage restoration
as well as improved pain and function until 5 years
postintervention.
The rate of additional surgical intervention such as high
tibial osteotomy and total knee arthroplasty was relatively
low and was similar in both groups (6.0% in the UCB-MSC-
HA group vs 7.6% in the microfracture group) during the
extended follow-up period. Most of the study patients were
middle-aged and physically active, and patients often con-
sider knee replacement or osteotomy as a last resort. There-
fore, we believe that only a few patients with severe
deterioration during the extended follow-up period under-
went replacement or osteotomy. Further long-term follow-
up may reveal the need for surgical reintervention after
treatment with UCB-MSC-HA composite compared with
microfracture.
This study has certain limitations. First, this study was
open-label to the patients and surgeons. However, it could
not be double-blinded because arthrotomy was performed on
the UCB-MSC-HA group and arthroscopy on the microfrac-
ture group. Sham surgery or microfracture using open
arthrotomy could have been the best control group, but the
regulatory authority and investigators agreed that such
measures would have been unethical or too aggressive. We
minimized bias by having blinded professionals assess the
primary outcome (ICRS Macroscopic Cartilage Repair
TABLE 4
Serious Adverse Events of Phase 3 Clinical Trial (48 weeks)
and Extended Follow-up Study (60 months)a
Serious Adverse Events UCB-MSC-HA Microfracture
Phase 3 clinical trial (n ¼ 50) (n ¼ 53)
Hepatitis B 0 (0.0) 1 (1.9)
Implant site pain 1 (2.0) 0 (0.0)
Pneumonia 1 (2.0) 1 (1.9)
Renal cancer 1 (2.0) 0 (0.0)
Extended follow-up study (n ¼ 36) (n ¼ 37)
Acute myocardial infarction 1 (2.8) 0 (0.0)
Bone operation 1 (2.8) 0 (0.0)
Contusion 0 (0) 1 (2.7)
Femur fracture 1 (2.8) 0 (0.0)
Hemorrhoid operation 1 (2.8) 0 (0.0)
Implant site pain 0 (0) 1 (2.7)
Liver abscess 1 (2.8) 0 (0.0)
Meniscectomy (intervention
knee)
0 (0.0) 1 (2.7)
Osteotomy (intervention knee) 1 (2.8) 1 (2.7)
Total knee arthroplasty
(intervention knee)
2 (5.6) 3 (8.1)
Rotator cuff syndrome 0 (0) 1 (2.7)
Spinal laminectomy 0 (0.0) 1 (2.7)
Spondylolisthesis 0 (0.0) 1 (2.7)
Uterine leiomyoma 1 (2.8) 0 (0)
Wheezing 1 (2.8) 0 (0)
aData are reported as n (%). UCB-MSC-HA, umbilical cord
blood–derived mesenchymal stem cells and 4% hyaluronate.
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Assessment score) as well as the secondary outcome (ICRS II
Histological Evaluation System score). Second, microfrac-
ture is not generally considered the standard care option for
the restoration of large, full-thickness cartilage defects,
especially in elderly patients. However, a placebo control
was not ethical or practical for our study patients, as dis-
cussed in the Methods. Implantation of HA only without
MSCs was also considered as a control intervention. How-
ever, the results of previous animal studies showed no mean-
ingful cartilage restoration with such a method.7,38 A third
limitation was that the participants received the interven-
tion for only the femoral cartilage defect in the “most
symptomatic” compartment. Thus, the effect of any
untreated lesion in the intervention joint could not be deter-
mined. However, the results of the present study reveal the
clinical benefit of treating only the most symptomatic lesion.
Further research on the treatment of multiple lesions is
warranted.
CONCLUSION
Implantation of UCB-MSC-HA resulted in improved carti-
lage grade at second-look arthroscopy at 48 weeks and pro-
vided more durable improvement of pain and function
compared with microfracture in patients with symptom-
atic, large, full-thickness cartilage defects. UCB-MSC-HA
appears to be a viable regenerative treatment option for
large, full-thickness cartilage defects of the knee in older
patients with osteoarthritis.
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APPENDIX TABLE A1
Inclusion and Exclusion Criteria for the Phase 3 (48-week) Studya
Inclusion Criteria Exclusion Criteria
Knee joint cartilage defect of International Cartilage Repair Society
grade 4, confirmed by arthroscopy (at screening, patients
diagnosed from magnetic resonance image may be included)
Male or female patients aged 18 years or older
Lesion size of 2-9 cm2 in 1 compartment (the compartment with the
most prominent symptoms)
Joint swelling, tenderness, and limitation of active range of motion of
grade 2
Pain 60 mm on a 100-mm visual analog scale in the affected joint
Adequate blood coagulation activity: prothrombin time
(international normalized ratio) <1.5, activated partial
thromboplastin time <1.5  control
Adequate renal function: creatinine 2.0 mg/dL; proteinuria
measured with dipstick of trace or less
Adequate hepatic function: bilirubin 2.0 mg/dL; aspartate
aminotransferase/alanine aminotransferase 100 IU/L
No surgery or radiation therapy in the affected joint within the past
6 weeks, and recovery from past treatments
For women of childbearing potential, agreement to practice adequate
birth control during the study
Ligament instability grade <2a on physical examination
Agreement to participate and signed informed consent
Current or past history of autoimmune disease
Infectious disease requiring antibiotics
Current or past myocardial infarction, ischemic heart failure, other
serious heart conditions, or uncontrolled hypertension
Serious medical comorbidity
Current pregnancy or nursing
Current or past psychotic diseases or epilepsy
Alcohol abuse
Heavy smoking
Chronic inflammatory articular disease such as rheumatoid arthritis
Current enrollment in any other clinical trial
Immunosuppressant use within the past 6 weeks
Ligament instability of grade 2a on physical examination
Known history of hypersensitivity or allergy to gentamicin
Any other condition for which the principal investigator considers
the patient inappropriate for participation in the trial (such as
Kellgren-Lawrence grade 4 osteoarthritis, significant deformity,
or previous osteotomy)
aLigamentous instability scale grades: grade 0, none; grade 1, 0-5 mm; grade 2, 5-10 mm; grade 3, >10 mm.
Appendix Figure A1. Preparation of umbilical cord blood–derived mesenchymal stem cell and 4% hyaluronate (UCB-MSC-HA)
composite. (A) UCB-MSC and the HA hydrogel were transported in a portable refrigerator to the hospital on the day of surgery. (B)
Cells were aspirated from the cell-containing vial before mixture. (C) Aspirated cells were transferred to the bottle containing the HA
sponge, and (D) the cells and HA sponge were mixed gently. (E) Prepared UCB-MSC-HA composite formed a gel. (F) UCB-MSC-
HA composite was transferred into a syringe for implantation. (G) UCB-MSC-HA composite was implanted into the drill holes. (H)
The hydrogel of UCB-MSC-HA composite could be kept in the drill holes without additional paste material. Bone bleeding within
the drill holes could permeate into the hydrogel that formed clots intermingled with the hydrogel.
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APPENDIX TABLE A2
ICRS Macroscopic Cartilage Repair Assessmenta
Cartilage Repair Assessment Points
Degree of defect repair
Level with surrounding cartilage 4
75% repair of defect depth 3
50% repair of defect depth 2
25% repair of defect depth 1
0% repair of defect depth 0
Integration to border zone
Complete integration with surrounding cartilage 4
Demarcating border <1 mm 3
3/4 of graft integrated, 1/4 with a border >1 mm 2
1/2 of graft integrated with surrounding cartilage, 1/2 with a border >1 mm 1
From no contact to 1/4 of graft integrated with surrounding cartilage 0
Macroscopic appearance
Intact, smooth surface 4
Fibrillated surface 3
Small, scattered fissures or cracks 2
Several small fissures or few but large fissures 1
Total degeneration of grafted area 0
Overall repair assessment
Grade 1: normal 12
Grade 2: nearly normal 11-8
Grade 3: abnormal 7-4
Grade 4: severely abnormal 3-1
aICRS, International Cartilage Repair Society.
APPENDIX TABLE A3




(n ¼ 39) P Value
Age, y 59.0 ± 7.7 59.0 ± 9.7 .970b
Sex .935c
Male 13 (34.2) 13 (33.3)
Female 25 (65.8) 26 (66.7)
Body mass index, kg/m2 26.3 ± 3.0 26.8 ± 3.5 .523b
Time since treatment, mo 38.3 ± 2.6 37.6 ± 2.6 .256b
Cartilage defect size, cm2 4.6 ± 1.8 4.2 ± 1.7 .297d
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APPENDIX TABLE A4
Details of Clinical Outcomes During Follow-upa





(n ¼ 46) P Value
Pain on 100-mm VASb 24.2 (17.5 to 31.0) 24.1 (18.3 to 29.9)
Improvement, baseline to 48 wk –19.7 (–11.6 to –27.9) –20.5 (–14.6 to –26.3) .887
WOMAC scorec 24.7 (20.5 to 28.9) 26.2 (21.1 to 31.2)
Improvement, baseline to 48 wk –12.8 (–8.3 to –17.2) –14.2 (–9.3 to –19.1) .661
IKDC score 53.4 (49.0 to 57.8) 53.5 (48.5 to 58.5)
Improvement, baseline to 48 wk 10.7 (7.0 to 14.4) 11.7 (7.6 to 15.7) .720





(n ¼ 37) P Value
Pain on 100-mm VAS
36 mo 30.9 (23.6 to 38.2) 41.1 (32.2 to 50.0)
Improvement, baseline to 36 mo –14.6 (–22.3 to –6.9) –3.6 (–12.6 to 5.4) .064
48 mo 35.7 (29.2 to 42.3) 43.3 (34.7 to 51,8)
Improvement, baseline to 48 mo –9.8 (–17.1 to –2.5) –1.4 (–10.1 to 7.2) .140
60 mo 29.1 (22.4 to 35.8) 43.5 (35.3 to 51.6)
Improvement, baseline to 60 mo –16.4 (–23.5 to –9.2) –1.2 (–8.1 to 5.6) .003
WOMAC score
36 mo 25.4 (19.9 to 31.0) 34.5 (27.2 to 41.8)
Improvement, baseline to 36 mo –14.7 (–20.3 to –9.2) –5.4 (–12.4 to 1.6) .036
48 mo 28.6 (22.4 to 34.9) 35.8 (27.6 to 44.1)
Improvement, baseline to 48 mo –11.5 (–17.3 to –5.7) –4.1 (–11.6 to 3.4) .119
60 mo 26.9 (20.4 to 33.5) 36.2 (28.6 to 43.8)
Improvement, baseline to 60 mo –13.2 (–18.7 to –7.8) –3.8 (–9.7 to 2.2) .020
IKDC score
36 mo 57.4 (50.8 to 64.1) 49.0 (43.3 to 54.7)
Improvement, baseline to 36 mo 17.3 (11.3 to 23.4) 7.0 (2.7 to 11.2) .006
48 mo 53.7 (48.2 to 59.3) 48.9 (42.1 to 55.7)
Improvement, baseline to 48 mo 13.6 (8.3 to 19.0) 6.8 (0.6 to 13.1) .098
60 mo 54.7 (48.7 to 60.7) 47.1 (41.1 to 53.2)
Improvement, baseline to 60 mo 14.6 (9.4 to 19.7) 5.1 (0.5 to 9.6) .007
aData are reported as mean (95% CI). IKDC, International Knee Documentation Committee; UCB-MSC-HA, umbilical cord blood–derived
mesenchymal stem cells and 4% hyaluronate; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis
Index.
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APPENDIX TABLE A5
Most Frequently Reported (5%) Treatment-Emergent







Nausea 15 (30.0) 12 (22.6)
Constipation 11 (22.0) 8 (15.1)
Headache 7 (14.0) 4 (7.6)
Dyspepsia 6 (12.0) 4 (7.6)
Dysuria 5 (10.0) 7 (13.2)
Pruritus 5 (10.0) 3 (5.7)
Implant site pruritus 5 (10.0) 1 (1.9)
Vomiting 4 (8.0) 1 (1.9)
Insomnia 4 (8.0) 1 (1.9)
Nasopharyngitis 3 (6.0) 4 (7.6)
Abdominal discomfort 3 (6.0) 2 (3.8)
Crepitations 3 (6.0) 2 (3.8)
Arthralgia 3 (6.0) 2 (3.8)
Diarrhea 3 (6.0) 1 (1.9)
Hypoesthesia 3 (6.0) 1 (1.9)
Micturition disorder 3 (6.0) 0 (0)
Dizziness 2 (4.0) 6 (11.3)
Cough 1 (2.0) 6 (11.3)
Hypertension 0 (0) 4 (7.6)
aData are reported as n (%). UCB-MSC-HA, umbilical cord
blood–derived mesenchymal stem cells and 4% hyaluronate.
APPENDIX TABLE A6
Most Frequently Reported (5%) Treatment-Emergent







Back pain 2 (5.6) 2 (5.4)
Toothache 2 (5.6) 1 (2.7)
Upper respiratory tract infection 2 (5.6) 1 (2.7)
Urinary tract infection 2 (5.6) 0 (0)
Nausea 2 (5.6) 0 (0)
Vomiting 2 (5.6) 0 (0)
Headache 2 (5.6) 0 (0)
Dysuria 2 (5.6) 0 (0)
Hematuria 2 (5.6) 0 (0)
Stress urinary incontinence 2 (5.6) 0 (0)
Allergic rhinitis 2 (5.6) 0 (0)
Arthralgia 1 (2.8) 3 (8.1)
Arthritis 0 (0) 2 (5.4)
Arthropathy 0 (0) 2 (5.4)
Hemorrhoids 0 (0) 2 (5.4)
Meniscal lesion 0 (0) 2 (5.4)
Blood glucose increase 0 (0) 2 (5.4)
aData are reported as n (%). UCB-MSC-HA, umbilical cord
blood–derived mesenchymal stem cells and 4% hyaluronate.
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